Literature DB >> 16772820

Topiramate-induced psychosis in patients with essential tremor: report of 2 cases.

Theresa A Zesiewicz1, Archer Tullidge, Jonathan Tidwell, Kelly L Sullivan, Robert A Hauser.   

Abstract

Two patients with essential tremor who had no psychiatric history developed symptoms of psychosis (visual hallucinations, paranoia, and vivid dreams) 3 days after starting topiramate (25 mg BID) for tremor control. All adverse symptoms resolved several days after topiramate was discontinued.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16772820     DOI： 10.1097/01.WNF.0000220823.80640.44

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


  6 in total

1.  Onset of paranoid delusions after addition of topiramate for seizure disorder treatment: a case report.

Authors:  Ahsan Mahmood
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  Topiramate-induced psychosis: the picture at 12 months.

Authors:  Anna Watkin; Faouzi Alam; Qaiser Javed
Journal:  BMJ Case Rep       Date:  2010-10-28

3.  Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features.

Authors:  Mikail Nourredine; Lucie Jurek; Bernard Angerville; Yannick Longuet; Julia de Ternay; Alain Derveaux; Benjamin Rolland
Journal:  CNS Drugs       Date:  2021-02-16       Impact factor: 5.749

4.  Topiramate-induced psychosis in two members of the one family: a case report.

Authors:  Ricardo Jorge Paixão José; Alastair Cairns; Christopher Babbs
Journal:  J Med Case Rep       Date:  2008-06-06

5.  Topiramate-Induced Acute Psychotic Symptoms: A Case Report.

Authors:  Hamed Jafarpour; Alireza Razavi; Kamal Alaedini; Maryam Sefidgarnia; Davood Hosseini Talari
Journal:  Clin Neuropsychiatry       Date:  2020-02

Review 6.  Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.

Authors:  Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez; Félix J Jiménez-Jiménez
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.